Abstract: Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.

Abstract: A block includes a first layer comprising a semi-solid material, and a second layer comprising an adhesive material, the second layer being attached to the first layer. The semi-solid material may include a deodorizing material, an antiperspirant material, a perfume-related substance, a sanitizing material, a sterilizing material, an air-freshening material, or an insect-repelling material. The block is disposed in an enclosed volume of a packaging, enclosed by a plastic layer and an aluminum foil layer.

Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Abstract: The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III containing 25-45% of peripheral amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia.

Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.

Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.

Abstract: The invention discloses an energy-providing bone-repair degradable porous scaffold, a preparation method thereof, and an application thereof. The invention obtains an energy-based biomaterial solution by compositing gelatin, a polyatomic acid and derivatives thereof, a dibasic alcohol and derivatives thereof, and a tribasic alcohol and derivatives thereof in a chemical cross-linking manner by using diisocyanate, and further obtains a porous scaffold through a drying method. The porous scaffold can avoid the problem of an acidic microenvironment caused by in vivo implantation of the existing biomaterial and keep the activity of an osteoblast cell, thereby improving the rate of repairing the damaged bone tissue with the energy-based biomaterial. The porous scaffold of the invention can be used as a filling material for bone repair in a surgical operation.

Abstract: A cosmetic applicator for providing a natural looking cosmetic benefit. The cosmetic applicator includes a substrate and a solid, transferrable cosmetic composition disposed on the substrate. The cosmetic composition is configured as a multitude of dots arranged in a discontinuous stochastic pattern. The cosmetic composition comprises a colorant dispersed in an adhesive.

Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Abstract: Described are personal care compositions comprising a polymer comprising: (a) one or more polymer comprising, as polymerized units, (i) 75% to 35% by weight, based on the weight of said polymer, one or more (meth)acrylate monomer selected from at least one of C1-C4 (meth)acrylate, (meth)acrylic acid, styrene, or substituted styrene, and (ii) 25% to 65% by weight, based on the weight of said polymer, one or more hydrophobic monomer, including hydrophobically substituted (meth)acrylate monomers, with alkyl chain length from C8 to C22 and, (iii) optionally crosslinker, and, (b) at least one personal care active. Optionally, the polymer further includes a stage 2 polymer comprising, as polymerized units, (i) 10-99% of one or more monomer which has a Tg of more than 80° C. after polymer formation, (ii) 1-10% of one or more (meth)acrylate monomer containing acid functional group, and (iii) optionally, a crosslinker.

Abstract: A deformable, dissolvable substance having a base material of gum paste capable of being deformed around a fishing hook. Other ingredients include powdered sugar, corn syrup, corn starch, butter, scent, and color. The scent is dispersed as the substance dissolves in water, thus attracting any fish finding the scent palatable.

Abstract: The present invention relates to cosmetics comprising a hydroxyl compound obtained by the reaction of a di- or higher-valent alcohol with a monovalent carboxylic acid and dimer acid, characterized in that the hydroxyl compound is obtained by reacting diglycerin with isostearic acid, and then reacting the obtained ester compound with dimer acid, wherein a molar ratio among diglycerin, isostearic acid and dimer acid is in the range of 1.0:1.4 to 1.6:0.5 to 0.8. The present invention provides cosmetics comprising the hydroxyl compounds having a high hydroxyl value.

Abstract: Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example.

Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.

Abstract: A method of preparing Adansonia digitata nanoparticles includes dissolving Adansonia digitata plant powder in an organic solvent to form a solution; spraying the solution in boiling water while applying ultrasonic energy to form a mixture; and stirring the mixture for at least about 15 minutes at a speed of about 200-800 rpm to obtain the Adansonia digitata nanoparticles.

Abstract: The invention relates to the use of fibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Abstract: An acidic aqueous composition having a pH of from 1 to 4, for elimination of spores of spore forming bacteria, comprises from 100 to 2000 ppm dissolved chlorine dioxide, and a surfactant system having a wetting effect and a spore solubilizing effect. The surfactant system comprises at least two hydrocarbon ionic surfactants stable for oxidation at the acidic pH, of which at least two surfactants have a difference in hydrocarbon chain length of at least four carbon atoms and are anionic surfactants at a pH of from 1 to 4, selected from the group consisting of soluble salts of alkyl sulphates, alkyl sulphonates, alkyl aryl sulphonates, and aryl sulphonates, having between 6 and 25 carbon atoms in the alkyl chains. Methods of eliminating spores of spore forming bacteria from the genus Clostridium on a surface comprise contacting the surface with an effective amount of the composition.

Abstract: Compositions, implantation devices and methods for stimulating an immune response to infection are discussed. In some examples, the compositions, implantation devices or methods of regulating the amplification of an adaptive immune response to infection involves use of one or more particles locally at a surgical or implant site to control bacterial infections without detrimental systemic side-effects. In some examples, the particles can be coated or layered onto the surface of an implantable device or material. In other examples, the particles can be injected into the site of implantation.

Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Abstract: Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.